Browsing Centre d'Esclerosi Múltiple de Catalunya - CEMCAT by Subject "Anticossos monoclonals"
Now showing items 1-2 of 2
-
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
(Lippincott Williams & Wilkins, 2021-10-19)



